SREBF1 and prostate cancer: In malignant glioma and prostate cancer, avasimibe-mediated SOAT1 inhibition could elevate intracellular cholesterol content, consequently impeding SREBP1 activity and SREBP1-modulated fatty acids synthesis and uptake10,12.